Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
N/A N=52 Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions
Hepatocellular Carcinoma
Primary: Arterial Fraction — 79.8; 72.2; 73.6 percentage of arterial fraction — p=0.211
N/A N=270 Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging
Liver Fibrosis
Primary: Liver Stiffness Measured by MRE — 3.07 kPa
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Phase 3 N=349 SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Liver Neoplasms
Primary: Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard — 53.2; 64.5; 41.1; 60.5 Percentage of true positive lesions — p=0.0754
N/A N=153 Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
Liver Diseases
Primary: Pathological Yield Fragmentation — 14; 11; 13; 10 mm
Phase 4 N=47 Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions
Hepatic Disease
Primary: Accuracy of CEUS at Differentiating Focal Nodular Hyperplasia (FNH) From Hepatocellular Adenoma (HCA) — 66.7; 64.0; 71.9; 90.6 percentage of lesions
Phase 2 N=44 Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Liver Cancer
Primary: Overall Image Quality of Magnetic Resonance Elastography (MRE)
N/A N=180 Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
Chronic Liver Disease · Non-Alcoholic Fatty Liver Disease · Hepatitis C Virus (HCV) Coinfection
Primary: Liver Elasticity Value Measured Using Sonoelastography (SE) — 7.225; 7.332; 8.548; 12.101 kilopascals (kPa)
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
N/A N=160 Controlled Attenuation Parameter (CAP) in Liver Allografts
Liver Transplant · Liver Steatosis · Liver Disease
Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m
Phase 1 N=10 Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
Liver Tumour
Primary: Concentration of Total Intratumoral Doxorubicin in Liver Tumour (Biopsies) Following Targeted Release of Doxorubicin From ThermoDox® ('Drug') Using Mild Hyperthermia…
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
Phase 2 N=25 Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Phase 3 N=353 SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
Liver Neoplasms
Primary: Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard — 48.7; 86.6; 35.3; 75.6 Percentage of true positive lesions — p=<.0001
N/A N=60 Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
Non-Alcoholic Fatty Liver Disease · Non-Alcoholic Steatohepatitis
Primary: Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements Hepatorenal Index (HRI) of Ultrasound Biomarkers for Liver Fat. — 1.6 Hepatorenal Index
Phase 2 N=39 Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
Phase 2 N=3 Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Liver Cancer · Liver Neoplasm · Hepatocellular Carcinoma
Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants
N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
Early Phase 1 N=9 Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
Fatty Liver
Primary: Hepatic Fatty Acid Oxidation
N/A N=142 Massive Iron Deposit Assessment
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Phase 2 N=151 TheraSphere for the Treatment of Liver Metastases
Colorectal Cancer · Carcinoma, Neuroendocrine · Neoplasm Metastasis
Primary: Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST) — 3.0; 17.9; 2.9; 3.4 Months
N/A N=21 Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Non-alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Median Total Specimen Length — 8; 14; 8; 11.5 mm
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
N/A N=67 Liver Cancer Community Education
Liver Cancer
Primary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale